Avricore Health (AVCR) AI Stock Analysis

• Market Cap: C$8.10M
• Dividend Yield: N/A
• Average Volume (3M): 51.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: -59.28%
• EPS Growth: -1563.64%
• Country: CA
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 101,289,665
• 10 Day Avg. Volume: 29,762
• 30 Day Avg. Volume: 51,367
• PEG Ratio: 1.92
• Price to Book (P/B): 2.80
• Price to Sales (P/S): 1.15
• P/FCF Ratio: 6.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.08 ▲(58.00% Upside)

The score is held down primarily by weak financial performance, led by a sharp TTM revenue decline, deep losses, and a return to free-cash-flow burn. Technicals provide some support with the stock trading above major moving averages and a positive MACD, but overbought signals (high RSI/Stoch) add risk. Valuation is constrained by a negative P/E and no dividend yield data.

Positive Factors

Pharmacy-based testing platform

Avricore’s core model pairs community pharmacies with a digital platform and operational support to deliver point-of-care testing. This creates recurring per-test and program revenue, leverages existing retail health footprints, and supports scalable rollouts that align with long-term outpatient care trends.

Low financial leverage

The company’s negligible debt reduces interest burden and financial distress risk, providing structural flexibility to invest in platform expansion or absorb temporary revenue shocks without immediate covenant pressure. This strengthens solvency prospects over the medium term.

Solid gross margins

A ~43% gross margin on testing and platform services indicates favorable unit economics for core services. High gross margins provide structural capacity to cover operating expenses as volumes scale and support sustainable profitability if revenue trends stabilize or recover.

Negative Factors

Sharp TTM revenue decline

A 37.6% TTM revenue contraction weakens scale economics and undermines the platform’s ability to leverage fixed costs. Sustained declines reduce bargaining power with pharmacy partners, limit reinvestment capacity, and raise the probability of needing external funding to support growth initiatives.

Persistent operating losses

A ~-46% net margin reflects inability to convert revenue into sustainable profits. Continued material losses erode equity and restrict reinvestment in product development and sales. Without durable margin improvement, the company risks dilution or constrained growth from limited retained capital.

Cash flow volatility and recent burn

The swing from positive FCF in 2024 to TTM cash burn signals execution and funding risk. Volatile cash generation increases likelihood of future capital raises, distracts management with financing needs, and can limit the company’s ability to scale programs or fulfil multi-site contracts reliably.

Avricore Health Business Overview & Revenue Model

Company Description

Avricore Health Inc. engages in the health data and point-of-care technologies business in Canada. It provides HealthTab, a lab-accurate point of care testing platform for pharmacy. The company has strategic partnerships with Shoppers Drug Marts and Abbott. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.

How the Company Makes Money

Avricore Health generates revenue through the sale and deployment of its HealthTab platform in partnership with pharmacies and healthcare providers. The company earns money by charging fees for each test conducted on its platform and through subscription models that allow pharmacies to access and utilize the HealthTab technology. Additionally, Avricore Health benefits from strategic partnerships with leading diagnostic and pharmaceutical companies, which may provide funding or revenue-sharing opportunities to further expand its market presence. The company's revenue model is heavily reliant on the adoption of its technology by healthcare networks and the volume of diagnostic tests performed.

Avricore Health Financial Statement Overview

Summary

Avricore Health demonstrates robust financial performance with strong revenue growth and operational efficiency. The balance sheet is solid with no debt, and cash flow management is improving. However, profitability remains an area for enhancement.

Income Statement

Avricore Health has shown significant improvement in its revenue, with a notable growth rate of 35.42% from the previous year. The company's gross profit margin stands at 37.94%, indicating strong cost management. However, the net profit margin is relatively low at 2.18%, which suggests room for improvement in profitability. Nevertheless, the positive trend in EBIT and EBITDA margins reflects a trajectory towards operational efficiency.

Balance Sheet

The balance sheet of Avricore Health is robust, with a strong equity ratio of 82.29%, indicating a solid financial foundation. The company has no debt, reflected in a debt-to-equity ratio of 0, which significantly reduces financial risk. Return on equity is positive at 4.14%, demonstrating effective utilization of shareholders' equity.

Cash Flow

Avricore Health's cash flow position is improving, with a strong operating cash flow to net income ratio of 8.78, indicating efficient cash management relative to earnings. The free cash flow to net income ratio is 3.41, showing a positive trend in generating free cash flow. The company has successfully shifted from negative to positive free cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.92M	4.79M	3.49M	1.77M	122.81K	33.03K
Gross Profit	834.20K	1.88M	1.20M	456.79K	30.52K	17.48K
EBITDA	-590.41K	-208.44K	-275.14K	-629.76K	-1.64M	-930.40K
Net Income	-1.63M	-668.98K	-701.22K	-818.23K	-1.71M	-1.17M
Balance Sheet
Total Assets	1.33M	2.30M	2.54M	2.57M	2.28M	440.09K
Cash, Cash Equivalents and Short-Term Investments	541.75K	1.14M	286.57K	630.53K	2.01M	302.71K
Total Debt	0.00	0.00	40.00K	40.00K	40.00K	1.00M
Total Liabilities	35.88K	330.82K	529.22K	604.89K	84.48K	1.15M
Stockholders Equity	1.29M	1.97M	2.01M	1.96M	2.20M	-714.04K
Cash Flow
Free Cash Flow	-263.03K	799.27K	-386.46K	-1.64M	-1.37M	-1.22M
Operating Cash Flow	-146.71K	1.00M	660.40K	-437.83K	-1.23M	-1.22M
Investing Cash Flow	-119.03K	-205.35K	-1.05M	-1.21M	-140.36K	0.00
Financing Cash Flow	17.50K	56.60K	42.50K	253.88K	3.08M	1.51M

Avricore Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AVCR, the sentiment is Positive. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 74.81 is Negative, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AVCR.

Avricore Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AVCR	47 Neutral	C$8.10M	-4.97	-71.97%	―	-59.28%	-1563.64%
BUX	47 Neutral	C$49.39M	-29.94	―	―	-21.89%	26.36%
TELO	44 Neutral	C$4.52M	-1.66	-9999.00%	―	―	19.05%
NARA	42 Neutral	C$7.44M	-1.67	―	―	―	81.01%
GLAB	41 Neutral	C$4.59M	-1.54	―	―	―	9.06%

Avricore Health Corporate Events

Avricore to Expand HealthTab Testing Network Across North East London Pharmacies

Avricore Health is expanding its HealthTab point-of-care testing platform across North East London, rolling out to an additional 70 community pharmacy sites following the success of its NHS-linked cardiovascular programmes with Barts Health NHS Trust. The move underscores growing national recognition of community pharmacies in cardiovascular care, aligns with NHS efforts to shift services from hospitals into the community, and demonstrates HealthTab’s scalability within complex NHS environments. By offering a turnkey, cloud-based infrastructure that integrates analyzers, patient results and quality-control data, and by partnering with reference lab CEQAL for rigorous quality management, Avricore is positioning HealthTab as a high-standard, scalable solution for preventive and treatment-linked care pathways across England.

The most recent analyst rating on (TSE:AVCR) stock is a Hold with a C$0.05 price target. To see the full list of analyst forecasts on Avricore Health stock, see the TSE:AVCR Stock Forecast page.

Avricore Health’s HealthTab Expands Role in NHS Cardiovascular Care Pilot

Avricore Health’s HealthTab platform is being utilized in a new pilot program by Barts Health NHS Trust to deliver cholesterol-lowering injections through community pharmacies in the UK. This initiative marks a significant expansion of HealthTab’s role from primary to secondary prevention, integrating with the Ortus-iHealth platform to connect pharmacy-generated results directly into hospital systems. Supported by a British Heart Foundation grant, the pilot aims to decentralize cardiovascular therapy, reduce hospital burdens, and enhance long-term lipid management, aligning with NHS policies to increase the role of community pharmacies in chronic condition management.